Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Does A Glp-1 Receptor Agonist Change Glucose Tolerance In Patients Treated With Antipsychotic Medications? Design Of A Randomised, Double-Blinded, Placebo-Controlled Clinical Trial, J. R. Larsen, L. Vedtofte, J. J. Holst, P. Oturai, A. Kjaer, Christoph Correll, T. Vilsboll, A. Fink-Jensen
Does A Glp-1 Receptor Agonist Change Glucose Tolerance In Patients Treated With Antipsychotic Medications? Design Of A Randomised, Double-Blinded, Placebo-Controlled Clinical Trial, J. R. Larsen, L. Vedtofte, J. J. Holst, P. Oturai, A. Kjaer, Christoph Correll, T. Vilsboll, A. Fink-Jensen
Journal Articles
Background Metabolic disturbances, obesity and life-shortening cardiovascular morbidity are major clinical problems among patients with antipsychotic treatment. Especially two of the most efficacious antipsychotics, clozapine and olanzapine, cause weight gain and metabolic disturbances. Additionally, patients with schizophrenia-spectrum disorders not infrequently consume alcohol. Glucagon-like peptide-1 (GLP-1) has shown to improve glycaemic control and reduce alcohol intake among patients with type 2 diabetes. Objectives To investigate whether the beneficial effects of GLP-1 analogues on glycaemic control and alcohol intake, in patients with type 2 diabetes, can be extended to a population of pre-diabetic psychiatric patients receiving antipsychotic treatment. Methods and analysis Trial …
Antipsychotic Treatment For Children And Adolescents With Schizophrenia Spectrum Disorders: Protocol For A Network Meta-Analysis Of Randomised Trials, A. K. Pagsberg, S. Tarp, D. Glintborg, A. D. Stenstrom, A. Fink-Jensen, Christoph Correll, R. Christensen
Antipsychotic Treatment For Children And Adolescents With Schizophrenia Spectrum Disorders: Protocol For A Network Meta-Analysis Of Randomised Trials, A. K. Pagsberg, S. Tarp, D. Glintborg, A. D. Stenstrom, A. Fink-Jensen, Christoph Correll, R. Christensen
Journal Articles
Introduction: Antipsychotic treatment in early-onset schizophrenia (EOS) lacks a rich evidence base, and efforts to rank different drugs concerning their efficacy have not proven any particular drug superior. In contrast to the literature regarding adult-onset schizophrenia (AOS), comparative effectiveness studies in children and adolescents are limited in number and size, and only a few meta-analyses based on conventional methodologies have been conducted. Methods and analyses: We will conduct a network meta-analysis of all randomised controlled trials (RCTs) that evaluate antipsychotic therapies for EOS to determine which compounds are efficacious, and to determine the relative efficacy and safety of these treatments …